Navigation Links
Watson Files Application for Generic SEASONIQUE(R)
Date:3/4/2008

CORONA, Calif., March 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. Watson's levonorgestrel and ethinyl estradiol product is a generic version of Barr's SEASONIQUE(R).

On January 23, 2008 pursuant to the Hatch-Waxman Act, Watson notified Barr that it had filed an ANDA with a paragraph IV certification with the FDA for a generic version of SEASONIQUE(R) asserting that the SEASONIQUE(R) patent is invalid or not infringed. Based on available information, Watson believes it may be the first applicant to file an ANDA for SEASONIQUE(R) and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

SEASONIQUE(R) is indicated for the prevention of pregnancy.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

SEASONIQUE(R) is a registered trademark of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... March 20, 2019 , ... AutismOne has announced that Dr. Andrew ... debate over measles. Dr. Wakefield's presentation at the AutismOne 2019 Conference will address what ... and vaccine eras. The lecture will examine the consequences - real and potential - ...
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... accelerates research commercialization, today launched THE BRAIN RACE, an open innovation contest to ... Brain Tumour Charity and Resonance Philanthropies, THE BRAIN RACE will launch 15+ startups ...
(Date:3/19/2019)... ... March 19, 2019 , ... Adult superstar, sex educator and exclusive Wicked ... to Wicked Sex: Senior Sex’ will begin production on April 17 in Los Angeles. ... newest edition of “Guide to Wicked Sex” brings together jessica drake with senior sex ...
(Date:3/19/2019)... ... March 19, 2019 , ... ... announced this week that Tracy Olsten, Compliance and Regional Practice Manager, will ... February 28. The Health Care Compliance Association (HCCA) is a 501(c)(6) member-based ...
(Date:3/18/2019)... ... ... With a three-year, $446,563 collaborative grant from the National Science Foundation, Kristen ... Institute (WPI), hopes to close an important gap in our understanding of physical factors ... important roles they play in the development of a wide range of disorders—from heart ...
Breaking Medicine News(10 mins):
(Date:3/19/2019)... ... ... TreTap Launches First-Ever CBD Infused Organic Tree Water Beverage , Public asked to ... TreTap beverages for a year , One of Vermont’s fastest growing organic brands ... acquired by Vermont’s original CBD store - Ceres Natural Remedies - in February, officially ...
(Date:3/19/2019)... , ... March 19, 2019 , ... ... clinical outcomes, today announced the winners of its 11th annual Intalere Healthcare Achievement ... innovative contributions to their patients, community and business partners in reducing healthcare costs, ...
(Date:3/18/2019)... ... March 18, 2019 , ... ART MEDICAL, a medical device ... publication of an article that outlines the limitations of current ICU nutrition methods ... patient care into the 21st Century. Pierre Singer, Professor of Anesthesia and ...
Breaking Medicine Technology: